New York, USA - September 25, 2024 - Immuno-oncology remains a dominant force in drug development, with approximately one-third of novel agents awaiting approval targeting cancer patients. As the pressure builds for cutting-edge treatments, Creative Biolabs has established the GTOnco™ platform to handle preclinical profiling and immune response monitoring, addressing the growing need for precision and efficacy in the rapidly evolving field of gene therapy-based I-O drug development.
At its core, GTOnco™ integrates a diverse range of assays and animal models to provide comprehensive profiling of immune responses, allowing scientists to rapidly identify promising therapeutic candidates. By utilizing advanced immuno-oncology assays, the platform offers clients the flexibility to choose the most suitable study design and screening methods. Here is a breakdown of how some of these assays work in tandem with the GTOnco™ platform to provide a robust toolkit for gene therapy-based immuno-oncology research:
• Immune System Activation Study: Crucial in understanding a drug's interaction with the immune system. Through this assay, researchers can evaluate how effectively a drug triggers the immune system to target and destroy cancer cells. It is essential for identifying therapies that can enhance immune response without causing unwanted side effects.
• Cytokine Response Assay: Help to profile the cytokine environment created by gene therapies, allowing researchers to predict the efficacy and safety of the drug. By measuring cytokine release and its effect on immune cells, the assay identifies therapies that effectively modulate the immune system without inducing harmful cytokine storms.
• T Cell Activation and Proliferation Assay: Pivotal in understanding how well a drug activates T-cells, which are key players in the immune system's ability to fight cancer. The assay allows researchers to assess the degree to which a therapy can activate and expand T cells in response to a tumor, ensuring that the treatment enhances the body's natural defenses. By optimizing T cell responses, this assay can lead to the development of therapies that provide longer-lasting immunity against cancer.
• T Cell Trafficking Assay: Evaluate the ability of engineered T cells to migrate effectively to the tumor environment. The better the T cells can travel and infiltrate the tumor, the more effective the treatment will be in real-world conditions. It is a critical step in developing therapies that can not only activate immune cells but also ensure they reach their target.
"GTOnco™ is particularly effective for identifying the best single-agent or combination therapies that promote tumor cell lysis, enhance T-cell proliferation and polarization, and boost natural killer cell function, which is a comprehensive solution for I-O drug developers looking to make significant strides in cancer treatment." The scientist added.
Visit https://www.creative-biolabs.com/gene-therapy to learn more.
Company Profile
With the FDA continuing to push boundaries in immuno-oncology and gene therapy approvals, Creative Biolabs remains at the cutting edge of innovation, helping researchers bring the next wave of cancer therapies to market. In 2024, a team of dedicated scientists will show up at the forthcoming industry exhibitions to share the latest advancements in biotech with peers.
• October 22, BioPharma Drug Discovery Nexus Conference
• November 4, World ADC San Diego
• December 15, Antibody Engineering & Therapeutics (US) 2024
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/gene-therapy
